SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Reshmi Chatterjee, Abhisek Mitra, An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer, International Immunopharmacology, 2015, 24, 2, 335

    CrossRef

  2. 2
    Mitsuru Ishizuka, Keiichi Kubota, Junji Kita, Mitsugi Shimoda, Masato Kato, Shozo Mori, Yukihiro Iso, Hidetsugu Yamagishi, Masaru Kojima, Aspartate aminotransferase-to-platelet ratio index is associated with liver cirrhosis in patients undergoing surgery for hepatocellular carcinoma, Journal of Surgical Research, 2015, 194, 1, 63

    CrossRef

  3. 3
    Mette J. Nielsen, Sanne S. Veidal, Morten A. Karsdal, Diana J. Ørsnes-Leeming, Ben Vainer, Stephen D. Gardner, Robert Hamatake, Zachary D. Goodman, Detlef Schuppan, Keyur Patel, Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C, Liver International, 2015, 35, 2
  4. 4
    F. W. D. Tai, W.-K. Syn, W. Alazawi, Practical approach to non-alcoholic fatty liver disease in patients with diabetes, Diabetic Medicine, 2015, 32, 4
  5. 5
    Jenni Hyysalo, Ville T. Männistö, You Zhou, Johanna Arola, Vesa Kärjä, Marja Leivonen, Anne Juuti, Nabil Jaser, Susanna Lallukka, Pirjo Käkelä, Sari Venesmaa, Marko Simonen, Juha Saltevo, Leena Moilanen, Eeva Korpi-Hyövalti, Sirkka Keinänen-Kiukaanniemi, Heikki Oksa, Marju Orho-Melander, Luca Valenti, Silvia Fargion, Jussi Pihlajamäki, Markku Peltonen, Hannele Yki-Järvinen, A population-based study on the prevalence of NASH using scores validated against liver histology, Journal of Hepatology, 2014, 60, 4, 839

    CrossRef

  6. 6
    Kerri A. Simo, Iain H. McKillop, Matthew T. McMillan, William A. Ahrens, Amanda L. Walters, Kyle J. Thompson, Timothy S. Kuwada, John B. Martinie, David A. Iannitti, Keith S. Gersin, David Sindram, Does a Calculated “NAFLD Fibrosis Score” Reliably Negate the Need for Liver Biopsy in Patients Undergoing Bariatric Surgery?, Obesity Surgery, 2014, 24, 1, 15

    CrossRef

  7. 7
    H. Kahal, G. Abouda, A. S. Rigby, A. M. Coady, E. S. Kilpatrick, S. L. Atkin, Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease, Clinical Endocrinology, 2014, 81, 4
  8. 8
    J. K. Dyson, Q. M. Anstee, S. McPherson, Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging, Frontline Gastroenterology, 2014, 5, 3, 211

    CrossRef

  9. 9
    Sean W.P. Koppe, Obesity and the liver: nonalcoholic fatty liver disease, Translational Research, 2014, 164, 4, 312

    CrossRef

  10. 10
    J. K. Dyson, S. McPherson, Q. M. Anstee, Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification, Postgraduate Medical Journal, 2014, 90, 1063, 254

    CrossRef

  11. 11
    M. A. Karsdal, H. Krarup, J. M. B. Sand, P. B. Christensen, J. Gerstoft, D. J. Leeming, N. Weis, O. B. Schaffalitzky de Muckadell, A. Krag, Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar, Alimentary Pharmacology & Therapeutics, 2014, 40, 3
  12. 12
    Wen Jianguo, Li Zhenzhen, Liu Xianghua, Zhao Zhanzheng, Sun Suke, Wang Suyun, Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in children, Clinica Chimica Acta, 2014, 434, 29

    CrossRef

  13. 13
    J. K. Dyson, S. McPherson, Q. M. Anstee, Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification, Journal of Clinical Pathology, 2013, 66, 12, 1033

    CrossRef

  14. 14
    Adrian Reuben, Drug-induced Liver Disease, 2013,

    CrossRef

  15. 15
    Llorenç Caballería, Pere Torán, Detección precoz de la enfermedad hepática crónica en población adulta aparentemente sana en atención primaria, Gastroenterología y Hepatología, 2012, 35, 23

    CrossRef